The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: A double-blind and placebo-controlled trial

Human Psychopharmacology

Volumn 31, Issue 2, 2016, Pages 103-112

  Iranpour, Negar ^a   Zandifar, Atefeh ^a   Farokhnia, Mehdi ^a   Goguol, Amirhossein ^a   Yekehtaz, Habibeh ^a   Khodaie Ardakani, Mohammad Reza ^b   Salehi, Bahman ^c   Esalatmanesh, Sophia ^a   Zeionoddini, Atefeh ^a   Mohammadinejad, Payam ^a   Zeinoddini, Arefeh ^a   Akhondzadeh, Shahin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

^c ARAK UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

clinical trial; negative symptoms; pioglitazone; schizophrenia; thiazolidinedione

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FLUPHENAZINE; GLUCOSE; HALOPERIDOL; HEMOGLOBIN A1C; INSULIN; OLANZAPINE; PIOGLITAZONE; PLACEBO; RISPERIDONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; NEUROLEPTIC AGENT;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOPULMONARY INSUFFICIENCY; CLINICAL ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EDEMA; EXTRAPYRAMIDAL SYMPTOM RATING SCALE; FEMALE; GLUCOSE BLOOD LEVEL; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HEBEPHRENIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCREASED APPETITE; INSOMNIA; INSULIN BLOOD LEVEL; LIVER DISEASE; MALE; MENTAL DISEASE ASSESSMENT; MYALGIA; NAUSEA; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PARALLEL DESIGN; PARANOID SCHIZOPHRENIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESIDUAL SCHIZOPHRENIA; SCHIZOPHRENIA; SIDE EFFECT; SORE THROAT; STOMACH PAIN; SWEATING; UNDIFFERENTIATED SCHIZOPHRENIA; CHRONIC DISEASE; COMBINATION DRUG THERAPY; IRAN; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IRAN; MALE; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84960093785     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2517     Document Type: Article

References (51)

1. Abbasi SH, Mohammadinejad P, Shahmansouri N, et al., 2015. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: A double-blind, placebo-controlled, randomized trial. J Affect Disord 183: 149-155.
2. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B,. 2007. Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial. Schizophr Res 90 (1-3): 179-185.
3. Al-Asmari A, Khan MW,. 2014. Inflammation and schizophrenia: Alterations in cytokine levels and perturbation in antioxidative defense systems. Hum Exp Toxicol 33 (2): 115-122.
4. Benedusi V, Martorana F, Brambilla L, Maggi A, Rossi D,. 2012. The peroxisome proliferator-activated receptor gamma (PPARgamma) controls natural protective mechanisms against lipid peroxidation in amyotrophic lateral sclerosis. J Biol Chem 287 (43): 35899-35911.
5. Brasier AR,. 2006. The NF-kappaB regulatory network. Cardiovasc Toxicol 6 (2): 111-130.
6. Buchanan RW,. 2007. Persistent negative symptoms in schizophrenia: An overview. Schizophr Bulletin 33 (4): 1013-1022.
7. Chouinard G, Margolese HC,. 2005. Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res 76 (2-3): 247-265.
8. Collino M, Aragno M, Mastrocola R, et al., 2006. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 530 (1-2): 70-80.
9. De Bosscher K, Vanden Berghe W, Haegeman G,. 2006. Cross-talk between nuclear receptors and nuclear factor kappaB. Oncogene 25 (51): 6868-6886.
10. Fan X, Song X,. 2013. Review: Non-steroidal anti-inflammatory drugs may reduce schizophrenia symptom severity in the short term when added to antipsychotics. Evid Based Ment Health 16 (1): 10.
11. Farokhnia M, Azarkolah A, Adinehfar F, et al., 2013. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: A randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 36 (6): 185-192.
12. Farokhnia M, Sabzabadi M, Pourmahmoud H, et al., 2014. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. Psychopharmacol (Berl) 231 (3): 533-542.
13. Feinstein DL,. 2003. Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol Ther 5 (1): 67-73.
14. Fenton WS, McGlashan TH,. 1991. Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry 48 (11): 978-986.
15. Gougol A, Zareh-Mohammadi N, Raheb S, et al., 2015. Simvastatin as an adjuvant therapy to fluoxetine inpatients with moderate to severe major depression: A double-blind placebo-controlled trial. J Psychopharmacol 29 (5): 575-581.
16. Ghaleiha A, Rasa SM, Nikoo M, Farokhnia M, Mohammadi MR, Akhondzadeh S,. 2015. A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism. Psychiatry Res 229 (1-2): 181-187.
17. Garcia-Bueno B, Madrigal JL, Lizasoain I, Moro MA, Lorenzo P, Leza JC,. 2005. Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats. Biol Psychiatry 57 (8): 885-894.
18. Gattaz WF, Brunner J, Schmitt A, Maras A,. 1994. Accelerated breakdown of membrane phospholipids in schizophrenia-implications for the hypofrontality hypothesis. Fortschr Neurol Psychiatr 62 (12): 489-496.
19. Hamilton M,. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
20. Horrobin DF,. 1996. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins leukot Essent Fatty Acids 55 (1-2): 3-7.
21. Hosseini SM, Farokhnia M, Rezaei F, et al., 2014. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: A randomized, double-blind, placebo-controlled, clinical trial. Eur Neuropsychopharmacol 24 (6): 846-855.
22. Hyong A, Jadhav V, Lee S, et al., 2008. Rosiglitazone, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents. Brain Res 1215: 218-224.
23. Kapadia R, Yi JH, Vemuganti R,. 2008. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 13: 1813-1826.
24. Kay SR, Fiszbein A, Opler LA,. 1987. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13 (2): 261-276.
25. Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, et al., 2014. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study. Psychiatry Res 215 (3): 540-546.
26. Kashani L, Omidvar T, Farazmand B, et al., 2013. Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. Psychoneuroendocrinology 38 (6): 767-776.
27. Kirkpatrick B, Fenton WS, Carpenter WT, Jr, Marder SR,. 2006. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 32 (2): 214-219.
28. Makinen J, Miettunen J, Isohanni M, Koponen H,. 2008. Negative symptoms in schizophrenia: A review. Nord J Psychiatry 62 (5): 334-341.
29. Martinez-Gras I, Perez-Nievas BG, Garcia-Bueno B, et al., 2011. The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia. Schizophr Res 128 (1-3): 15-22.
30. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA,. 2012. Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17 (12): 1206-1227.
31. Muller N, Krause D, Dehning S, et al., 2010. Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 121 (1-3): 118-124.
32. Muller N, Myint AM, Schwarz MJ,. 2012. Inflammation in schizophrenia. Adv Protein Chem Struct Biol 88: 49-68.
33. Muller N, Schwarz M,. 2006. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res 10 (2): 131-148.
34. Munhoz CD, Garcia-Bueno B, Madrigal JL, Lepsch LB, Scavone C, Leza JC,. 2008. Stress-induced neuroinflammation: Mechanisms and new pharmacological targets. Braz J Med Biol Res 41 (12): 1037-1046.
35. O'Donnell P,. 2012. Cortical interneurons, immune factors and oxidative stress as early targets for schizophrenia. Eur J Neurosci 35 (12): 1866-1870.
36. Potkin SG, Alva G, Fleming K, et al., 2002. A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography. Am J Psychiatry 159 (2): 227-237.
37. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E,. 2008. Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review. Biol Psychiatry 63 (8): 801-808.
38. Qi L, Jacob A, Wang P, Wu R,. 2010. Peroxisome proliferator activated receptor-gamma and traumatic brain injury. Int J Clin Exp Med 3 (4): 283-292.
39. Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, Kerkeni A,. 2009. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 33 (7): 1178-1183.
40. Richard MD, Brahm NC,. 2012. Schizophrenia and the immune system: Pathophysiology, prevention, and treatment. Am J Health Syst Pharmacy 69 (9): 757-766.
41. Sandouk T, Reda D, Hofmann C,. 1993. The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability. Endocrinol 133 (1): 352-359.
42. Schoepf D, Potluri R, Uppal H, Natalwala A, Narendran P, Heun R,. 2012. Type-2 diabetes mellitus in schizophrenia: Increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up. Eur Psychiatry 27 (1): 33-42.
43. Shimazu T, Inoue I, Araki N, et al., 2005. A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke 36 (2): 353-359.
44. Smith RC, Jin H, Li C, et al., 2013. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: A randomized double-blind study. Schizophr Res 143 (1): 18-24.
45. Smith U,. 2001. Pioglitazone: Mechanism of action. Int J Clin Pract 121 (Suppl): 13-18.
46. Sepanjnia K, Modabbernia A, Ashrafi M, Modabbernia MJ, Akhondzadeh S,. 2012. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: Randomized double-blind placebo-controlled trial. Neuropsychopharmacology 37 (9): 2093-2100.
47. Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir S,. 2010. Hypoglycaemia with pioglitazone: Analysis of data from the prescription-event monitoring study. J Eval Clin Prac 16 (6): 1124-1128.
48. Wu JC, D A, Hs B,. 2000. Neuroimaging in clinical practice. In Kaplan and Sadock's Comprehensive Textbook of Psychiatry, 7th edn, Sadock Benjamine James, Sadock Virginia Alcot, (eds). Williams & Wilkins: New York; 373-385.
49. Zhao X, Zhang Y, Strong R, Grotta JC, Aronowski J,. 2006a. 15d-prostaglandin J2 activates peroxisome proliferator-activated receptor-gamma, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats. J Cereb Blood Flow Metab 26 (6): 811-820.
50. Zhao Y, Patzer A, Herdegen T, Gohlke P, Culman J,. 2006b. Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J 20 (8): 1162-1175.
51. Zeinoddini A, Sorayani M, Hassanzadeh E, et al., 2015. Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: A randomized, double-blind, placebo-controlled trial. Depress Anxiety 32 (3): 167-173.